On March 17, 2026 Knight Therapeutics Inc., (TSX: GUD) ("Knight") a pan-American (ex-USA) specialty pharmaceutical company, reported that its Brazilian affiliate, United Medical Ltda. has received approval from ANVISA, the Brazilian health regulatory agency, for an additional indication for MINJUVI (tafasitamab). The approval follows a supplemental regulatory filing and review by ANVISA under Project Orbis for MINJUVI, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). 1

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The approval is supported by data from clinical studies evaluating MINJUVI in combination with rituximab and lenalidomide (R2), which demonstrated meaningful response rates and durable disease control in patients with previously treated FL.

"ANVISA’s approval of the new indication for tafasitamab in combination with rituximab and lenalidomide represents an important step in expanding treatment options for patients with relapsed or refractory follicular lymphoma. As a chemotherapy-free option with a favorable risk-benefit profile, this approval broadens therapeutic alternatives for patients across Brazil," said Dr Jorge Vaz Pinto Neto, Hematologist, Member of The Board of Directors of the Brazilian Association of Hematology, Hemotherapy, and Cellular Therapy (ABHH-TC) and Coordinator of the Bone Marrow Transplant Unity at CETTRO Cancer Center/ Oncoclinicas – Brasília.

"This approval of MINJUVI delivers on our promise to bring high quality cancer care to Latin America and provides physicians and patients a new option in the treatment of relapsed or refractory lymphoma," said Samira Sakhia, President and CEO of Knight Therapeutics Inc. "The rapid review and approval under Project Orbis reflect Knight’s strong regulatory capabilities and focused execution for the benefit of Knight and our partners."

Knight entered into an exclusive supply and distribution agreement with Incyte (NASDAQ: INCY) in 2021 for tafasitamab (commercialized as MONJUVI (tafasitamab-cxix) in the United States and MINJUVI ex-USA) across Latin America. Knight has launched MINJUVI in Brazil, Mexico and Argentina for use in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLCBL arising from low grade lymphoma in Brazil, who are not eligible for autologous stem cell transplantation (ASCT).

About MINJUVI (tafasitamab)

MINJUVI (tafasitamab) is a humanized Fc-modified cytolytic CD19 targeting monoclonal antibody. Tafasitamab incorporates an XmAb engineered Fc domain, which mediates B-cell lysis through apoptosis and immune effector mechanism including Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC) and Antibody-Dependent Cellular Phagocytosis (ADCP). Incyte licenses exclusive worldwide rights to develop and commercialize tafasitamab from Xencor, Inc.

In the U.S., MONJUVI is approved by the U.S. FDA in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL).

MONJUVI is not approved and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials.

Additionally, MONJUVI received accelerated approval in the United States in combination with lenalidomide for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

In Europe, MINJUVI (tafasitamab) received conditional Marketing Authorization from the European Medicines Agency in combination with lenalidomide, followed by MINJUVI monotherapy, for the treatment of adult patients with relapsed or refractory DLBCL who are not eligible for ASCT. Additionally, MINJUVI is approved in combination with lenalidomide and rituximab for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) (Grade 1-3a) after at least one line of systemic therapy in Europe.

In Japan, MINJUVI is approved in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL).

In Brazil, MINJUVI is approved for use in combination with lenalidomide followed by MINJUVI monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), including DLCBL arising from low grade lymphoma in Brazil, who are not eligible for autologous stem cell transplantation (ASCT) and is also approved in MINJUVI, in combination with rituximab and lenalidomide for the treatment of adult patients with relapsed or refractory follicular lymphoma (FL). MINJUVI is not approved and is not recommended for the treatment of patients with relapsed or refractory marginal zone lymphoma outside of controlled clinical trials.

XmAb is a registered trademark of Xencor, Inc.

MONJUVI and MINJUVI are registered trademarks of Incyte.

About Follicular Lymphoma (FL)

FL is the most common subtype of indolent non-hodgkin lymphoma (NHL).2-4 FL typically presents with generalized painless lymphadenopathy that waxes and wanes. It commonly affects the axillary, cervical, femoral, and inguinal lymph nodes. Rarely, it may appear as an asymptomatic large mediastinal mass. Roughly 20% of FL patients experience B symptoms such as night sweats, fever, and weight loss.5 Although patients usually respond to initial therapy, FL will typically relapse over time and is therefore considered incurable.6,7 Approximately a quarter of FL patients are refractory to first-line immunochemotherapy.8 Additionally, there is a risk of histologic transformation to DLBCL or high-grade B-cell lymphomas, which occurs at an estimated annual rate of 2% to 3% and is generally associated with a poor clinical outcomes.9-12

In Brazil, according to the 2023 data from the INCA Registries, the expected incidence/year of NHL (inclusive of all subtypes) was 5.57 per 100, 000 in the general population.13 It is expected that follicular lymphoma constitutes 20% to 25% of adult NHL cases.2-4 Globally it is believed to have an estimated prevalence of 1/3000 thus making it a rare disease by both Global and Brazilian regulatory standards.14

About inMIND Study

The inMIND study (INCMOR 0208-301) was a Phase 3, randomized, double-blind, placebo-controlled, multicenter study in participants with relapsed/refractory FL or relapsed/refractory marginal zone lymphoma (MZL) who had been previously treated with at least one prior line of systemic therapy, including an anti-CD20 antibody. Patients were randomized to receive either tafasitamab + R2 (n = 273) versus placebo + R2 (n = 275). The estimated median progression free survival (PFS; primary endpoint) was 22.37 months (95% CI: 19.22, NE) in the tafasitamab + R2 group compared with 13.93 months (95% CI: 11.53, 16.39) in the placebo + R2 group, with a HR of 0.434 (95% CI: 0.324, 0.580) and a p < 0.0001. Overall, adding tafasitamab to lenalidomide plus rituximab led to a statistically significant, clinically meaningful improvement in PFS, corresponding to a 57% lower risk of progression, relapse, or death in patients with relapsed/refractory follicular lymphoma.15 The most common adverse reactions (≥ 20%) in patients with relapsed or refractory FL were respiratory tract infections, diarrhea, rash, fatigue, constipation, musculoskeletal pain, and cough. The most common Grade 3 or 4 laboratory abnormalities (≥ 20%) were decreased neutrophils and decreased lymphocytes.

(Press release, Knight Therapeutics, MAR 17, 2026, View Source [SID1234663627])

On March 17, 2026 Aarvik Therapeutics, an innovative, ADC-focused biotechnology company dedicated to engineering precision medicines for cancer therapy, reported that it will present two posters and a minisymposium talk at the AACR (Free AACR Whitepaper) Annual Meeting 2026. These presentations display the breadth of Aarvik’s capabilities in the ADC space. The AACR (Free AACR Whitepaper) Annual Meeting will take place from April 17-22, 2026, in San Diego, California.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Aarvik, along with collaborator ArriVent BioPharma, Inc. (Nasdaq: AVBP), will present a poster titled "AV-P138-ADC (ARR-002), a novel MUC16/NaPi2b dual-target tetravalent ADC, for the treatment of ovarian and endometrial cancers" (Poster Number 2660). AV-P138-ADC, also known as ARR-002, was discovered by Aarvik as part of a research collaboration with ArriVent, who subsequently exclusively licensed the molecule and plans global development. AV-P138-ADC (ARR-002) is a novel, site-specifically-conjugated, dual-target tetravalent ADC that may overcome the limitations of conventional single-target or bivalent bispecific ADCs to potentially provide a safer and more effective treatment option for a broad spectrum of ovarian and endometrial cancer patients.

Poster Details

Date and Time: Monday April 20, 2026 from 9 AM – 12 PM PT
Session Category, Title: Clinical Research, Targeted Antigen Therapies and Immunity
Location: Section 49, Board 12, Number 2660

Further illustrating the power of Aarvik’s proprietary MUTTA platform, the oral presentation titled "MUlti-epitope Targeting Tetravalent Antibody (MUTTA) platform for Developing NextGen ADCs with an Improved Therapeutic Window" (Abstract Presentation Number 6758) will demonstrate in vitro and in vivo validation of multi-target MUTTA ADCs and their improved therapeutic window compared to single-target ADCs, as well as the broad applicability of the MUTTA platform across several tumor antigens.

Minisymposium Details

Date and Time: Tuesday April 21, 2026 from 2:30 – 4:30 PM PT
Session Category, Title: Clinical Research, Targeted Therapy: Data Driven Approaches and Novel Drugs

Aarvik will also present a poster titled "Exatecan Payload-Based Antibody-Drug Conjugates with a Short Hydrophilic beta-Glucuronidase Cleavable Linker" (Poster Number 5757). This poster will demonstrate data on one of the novel linker-payloads engineered utilizing Aarvik’s proprietary AQUALINK platform that is designed to develop next generation ADCs with superior hydrophilic properties.

Poster Details

Date and Time: Tuesday April 21, 2026 from 2 – 5 PM PT
Session Category, Title: Experimental and Molecular Therapeutics, Multi-Axis Antineoplastic Agents
Location: Section 14, Board 15, Number 5757

"We are pleased to present data at AACR (Free AACR Whitepaper) 2026 resulting from Aarvik’s deep expertise in engineering proprietary multispecific antibodies, linkers and payloads through Aarvik’s MUTTA and AQUALINK platforms," said Jagath Reddy Junutula, PhD, Co-founder, President and CEO of Aarvik Therapeutics. "These presentations showcase the success that Aarvik continues to demonstrate as it relentlessly pursues novel therapies for hard-to-treat cancer indications through research and innovation."

"Aarvik continues to generate exciting data from the MUTTA and AQUALINK platforms," said Paul Polakis, PhD, Aarvik Fellow and Scientific Advisory Board member. "Aarvik’s approach, along with the other new approaches in the ADC field overall, can result in novel therapies for patients with cancer."

(Press release, Aarvik Therapeutics, MAR 17, 2026, View Source [SID1234663643])

On March 17, 2026 Zymeworks Inc. (Nasdaq: ZYME), a biotechnology company managing a portfolio of licensed healthcare assets while developing a diverse pipeline of novel, multifunctional biotherapeutics, reported the acceptance of an oral presentation and six abstracts from its wholly-owned R&D portfolio for poster presentation at the upcoming American Association for Cancer Research (AACR) (Free AACR Whitepaper) Annual Meeting, held April 17-22, 2026 in San Diego, CA.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are excited to share new clinical and preclinical updates at AACR (Free AACR Whitepaper) that highlight the breadth of our ADC portfolio and the continued evolution of our platform technologies," said Paul Moore, Ph.D., Chief Scientific Officer at Zymeworks. "In addition to new preclinical combination insights from our ADC candidate ZW191, we will present data from our emerging RAS inhibitor ADC platform and several novel candidates designed to target treatment of RAS mutated cancers, some of the most prevalent oncogenic-driven human cancer types. Together, these findings demonstrate our differentiated approach to ADC design and our commitment to developing innovative therapies for patients with difficult-to-treat cancers."

Oral Presentation Details

Title: Results from Part 1 dose escalation of ZWI-ZW191-101 study: Phase 1 first-in-human multicenter open-label study of ZW191, a folate receptor α (FRα)–targeting antibody-drug conjugate (ADC), in participants with advanced solid tumors
Abstract: CT306
Session: Advances in Precision Oncology
Date/Time: Tuesday, April 21, 2026 at 2:30 – 4:30 pm Pacific Standard Time (PST)

"We look forward to presenting additional clinical data from Part 1 of our Phase 1 trial of ZW191, our FR alpha targeting ADC with our proprietary topoisomerase 1 inhibitor payload, in patients with advanced solid tumors," said Sabeen Mekan, M.D., Senior Vice President and Chief Medical Officer of Zymeworks. "The more mature results build on the initial data we presented at the AACR (Free AACR Whitepaper)-EORTC-NCI conference in October 2025 and further reinforce our confidence in the potential ZW191 to be a well-tolerated and effective agent that is potentially best-in-class for patients with advanced, heavily pretreated cancers. We remain excited to advance ZW191 through the ongoing Part 2 of our Phase 1 trial and to explore strategic opportunities that could help maximize the potential of this program for patients."

Poster Presentation Details

Title: ZW191 – a differentiated FRα-targeted topoisomerase I antibody drug conjugate active in combination with standard of care drugs
Abstract: 7500
Session: Experimental and Molecular Therapeutics
Date/Time: Monday, April 20, 2026 at 9:00 am – 12:00 pm PST

ZW191 is a clinical-stage ADC targeting folate receptor alpha (FRα), currently under investigation in patients with advanced ovarian, endometrial, and non-small cell lung cancers (NSCLC). New preclinical data demonstrate strong anti-tumor activity when ZW191 is combined with standard-of-care agents, including carboplatin, paclitaxel, bevacizumab, and PARP inhibitors, driven by enhanced DNA damage in tumor cells. Together with encouraging early clinical data highlighting ZW191’s single-agent activity and differentiated safety profile, the findings support its potential to deliver meaningful efficacy improvements across multiple cancer types and treatment settings.

Title: A pan-RASi antibody-drug conjugate platform with high activity in RAS-mutant cancers
Abstract: 5140
Session: Experimental and Molecular Therapeutics
Date/Time: Monday, April 20, 2026 at 9:00 am – 12:00 pm PST

A novel ADC platform has been developed to overcome the efficacy and tolerability limitations of current oral pan-RAS inhibitors, which despite clinical promise are associated with on-target toxicities in normal tissues. The platform incorporates newly synthesized pan-RAS inhibitor payloads demonstrating higher potency than the clinical benchmark RMC-6236, with optimized drug-linkers showing strong tumor regressions at low doses and no significant toxicity at high doses in preclinical models. These findings establish a highly promising pan-RASi ADC platform with the potential to deliver improved efficacy and tolerability across multiple RAS-driven cancers, including NSCLC, pancreatic, and colorectal cancer.

Title: Development of ZW418, a biparatopic PTK7-targeting antibody-drug conjugate incorporating a novel pan-RAS inhibitor payload for the treatment of non-small cell lung cancer
Abstract: 4944
Session: Experimental and Molecular Therapeutics
Date/Time: Monday, April 20, 2026 at 9:00 am – 12:00 pm PST

ZW418 is a novel biparatopic ADC targeting PTK7, a protein broadly overexpressed in NSCLC, and delivering a novel pan-RAS inhibitor payload designed to improve upon the efficacy and tolerability limitations of current RAS inhibitors. Preclinical data demonstrate superior internalization and tumor penetration compared to clinical benchmark PTK7-targeted antibodies, alongside potent and targeted tumor cell killing and strong anti-tumor activity across multiple RAS-mutated cancer models. These findings support ZW418’s potential as a highly differentiated therapeutic for NSCLC patients whose tumors are driven by RAS mutations.

Title: ZW427, a Ly6E-targeting antibody drug conjugate bearing a novel pan-RAS inhibitor payload for the treatment of RAS mutated cancers
Abstract: 7715
Session: Experimental and Molecular Therapeutics
Date/Time: Tuesday, April 21, 2026 at 9:00 am – 12:00 pm PST

ZW427 is a novel ADC targeting Ly6E, a protein broadly overexpressed across multiple solid tumors, and delivering a novel pan-RAS inhibitor payload designed to improve upon the efficacy and tolerability limitations of current small molecule RAS inhibitors. Preclinical data demonstrate ZW427’s potent and targeted tumor cell killing, strong bystander activity, and anti-tumor activity across multiple RAS-mutated cancer models including NSCLC, pancreatic, and colorectal cancers. These findings support ZW427’s potential as a highly differentiated therapeutic for the large population of cancer patients whose tumors are driven by aberrant RAS signaling.

Title: ZW439, a novel CLDN18.2-targeting pan-RAS inhibitor antibody drug conjugate for the treatment of RAS mutated pancreatic cancer
Abstract: 4456
Session: Experimental and Molecular Therapeutics
Date/Time: Tuesday, April 21, 2026 at 2:00 – 5:00 pm PST

ZW439 is a novel ADC targeting Claudin 18.2 (CLDN18.2) and delivering a novel pan-RAS inhibitor payload, designed to address the urgent unmet need in pancreatic cancer. Preclinical data demonstrate ZW439’s potent and targeted tumor cell killing across a range of CLDN18.2 expression levels, strong bystander activity, and highly efficacious anti-tumor activity in multiple cancer models, alongside an encouraging tolerability profile. These findings support ZW439’s potential as a differentiated therapeutic for patients with pancreatic cancer and other difficult-to-treat tumors driven by RAS mutations.

Title: Design and evaluation of mRNA translation inhibitors for use as antibody drug conjugate payloads
Abstract: 2062
Session: Chemistry
Date/Time: Monday, April 20, 2026 at 9:00 am – 12:00 pm PST

A novel ADC platform has been developed incorporating newly synthesized eIF4A inhibitor payloads, which block translation of key oncogenic proteins including MYC and KRAS, offering a differentiated mechanism with the potential to address resistance seen with other ADC payload classes. Preclinical data demonstrate potent and targeted tumor cell killing in vitro and promising anti-tumor activity across multiple clinically relevant targets in vivo, including HER2, Ly6E, TROP2, and EGFR.

The AACR (Free AACR Whitepaper) abstracts are available at View Source!/21436.

Invited Talks

Senior members of Zymeworks’ research team will be speaking at the following sessions:

Title: Unlocking novel biologies with bi- and trispecific antibodies: the importance of antibody format
Speaker: Dr. Nina Weisser, Senior Director, Preclinical Multispecific Antibody Therapeutics
Date/Time: Wednesday, April 22, 2026 at 2:00 – 5:00 pm PST

Title: The (r)evolution of antibody-drug conjugates: From early concepts to next-generation cancer therapy
Speaker: Dr. Raffaele Colombo, Director, Medicinal Chemistry
Date/Time: Wednesday, April 22, 2026 at 8:32 – 8:59 am PST

About ZW191
ZW191 is an antibody-drug conjugate engineered to target a protein called folate receptor-⍺ found in ~75% of high-grade serous ovarian carcinomas1 and ~70% of lung adenocarcinomas2. ZW191’s differentiated design strongly supports its ability to internalize into FR⍺-expressing cells with the potential to release bystander active topoisomerase-1 inhibitor (ZD06519), a novel proprietary payload developed by Zymeworks to kill tumor cells.

ZW191 is currently being evaluated in a Phase 1 clinical study to assess its safety, tolerability, pharmacokinetics, and preliminary anti-tumor activity in participants with advanced solid tumors (NCT06555744). The study is designed to further characterize ZW191’s clinical activity and safety to inform its future development strategy.

(Press release, Zymeworks, MAR 17, 2026, View Source [SID1234663659])

On March 17, 2026 Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, reported that the U.S. Food and Drug Administration (FDA) has approved the MyChoice CDx Test as the Companion Diagnostic (CDx) for Zejula (niraparib), a PARP inhibitor from GSK, for patients with advanced ovarian cancer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

This approval is based on final data from the PRIMA trial, where the MyChoice CDx Test determined homologous recombination deficiency (HRD) status and was used to stratify advanced ovarian cancer patients.

The MyChoice CDx is the only FDA-approved companion diagnostic test in the United States to identify patients with HRD-positive status eligible for treatment with Zejula. The test determines HRD status by leveraging next generation sequencing technology to conduct a comprehensive assessment of BRCA1/2 genes — including large rearrangements — and tumor genomic instability score (GIS) that includes loss of heterozygosity (LOH), telomeric allelic imbalance (TAI) and large-scale state transitions (LST).

"The FDA approval reinforces Myriad’s long-standing leadership in ovarian cancer diagnostics and underscores the clinical importance of comprehensive HRD testing," said Brian Donnelly, Chief Commercial Officer, Myriad Genetics. "By enabling precise identification of patients who may benefit from PARP inhibitors, MyChoice CDx helps ensure that treatment decisions are guided by robust genomic insights."

Nearly 50% of patients with advanced ovarian cancer have HRD positive (HRD+) tumors.1 Identifying these patients is critical to ensuring appropriate use of PARP inhibitor therapy and improving personalized treatment decisions.1-4

Zejula is a prescription medicine used for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer whose cancer is associated with HRD+ status defined by a deleterious or suspected deleterious BRCA mutation and/or genomic instability. Zejula is used after the cancer has responded (complete or partial response) to treatment with first-line platinum-based chemotherapy (Zejula indications referenced here apply to the US only). (For other indications, see "About Zejula" section below).

To learn more about the MyChoice CDx Test and how it can support treatment decisions for patients eligible for Zejula, please visit View Source

About the MyChoice CDx Test
The MyChoice CDx Test is the only FDA-approved homologous recombination deficiency (HRD) test specifically mentioned in American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) guidelines for selecting patients with ovarian cancer who may benefit from poly [ADP-ribose] polymerase (PARP) inhibitors.5 The MyChoice CDx Test determines HRD status by conducting a comprehensive assessment of BRCA1/2 genes and tumor genomic instability score (GIS) that includes loss of heterozygosity (LOH), telomeric allelic imbalance (TAI) and large-scale state transitions (LST). The MyChoice CDx Test can identify 34% more patients with HRD than other tumor tests that use %LOH alone.1

About Zejula (niraparib)
Zejula is an oral, once-daily poly (ADP ribose) polymerase (PARP) inhibitor that works by preventing DNA repair in tumor cells, ultimately leading to their death. Zejula is indicated in the US for the maintenance treatment of adult patients with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in complete or partial response to first-line platinum-based chemotherapy and whose cancer is associated with homologous recombination deficiency (HRD)-positive status.

Zejula is also indicated for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy and who have been selected based on a US FDA-approved companion diagnostic for Zejula (Zejula indications referenced here apply to the US only).

(Press release, Myriad Genetics, MAR 17, 2026, View Source [SID1234663676])

On March 17, 2026 Prescient Therapeutics Ltd (ASX:PTX) is advancing enrolment in its Phase 2 clinical trial for lead asset PTX-100, with new research highlighting steady progress across trial execution, regulatory milestones and funding — while pointing to valuation upside from current levels.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A new report from Pitt Street Research outlines growing momentum behind PTX-100, a first-in-class oncology drug targeting relapsed or refractory cutaneous T-cell lymphoma (CTCL), a rare and difficult-to-treat cancer where treatment options remain limited.

5
The therapy works by inhibiting GGTase-1, a pathway involved in cancer cell signalling and survival, offering a differentiated approach compared with existing treatment classes.

Phase 2 footprint expands
The Pitt Street report noted that Prescient’s Phase 2 trial continues to scale, with eight of a planned 16 global sites now established and enrolling patients.

The study is structured in two stages, beginning with dose optimisation before expanding into a broader efficacy and safety phase. Key endpoints include objective response rate, along with progression-free survival and duration of response.

Clinical sites across the US and Australia are already active, with European expansion underway — a key step expected to support recruitment in a relatively small and specialised patient population.

The report highlights European site activation as a critical near-term driver, particularly as new investigators come on board to help lift enrolment rates and accelerate data flow through 2026.

Early data supports differentiated approach
While Phase 2 remains in its early stages, the investment case continues to be anchored by encouraging Phase 1 results.

PTX-100 delivered a 43% overall response rate and a 100% clinical benefit rate in earlier studies, alongside a favourable safety profile with no serious adverse events attributed to the drug.

That combination is particularly relevant in CTCL, where existing therapies often struggle to deliver durable responses without significant side effects.

The research note argues the drug’s unique mechanism and early data position it as a potentially differentiated option in this setting, while also opening the door to broader applications across other cancers.

"PTX-100’s status as the only GGTase-1 inhibitor in clinical development anywhere in the world, and one with far more promising results than any TCL drugs on the market, gives it a uniqueness that is attractive to potential pharmaceutical partners."

Regulatory progress and funding support
Recent regulatory milestones are also strengthening the commercial outlook.

PTX-100 has secured orphan drug designation in both the US and Europe for CTCL, providing incentives such as market exclusivity, regulatory support and reduced fees — factors that can help streamline development and improve long-term economics.

Prescient has also reinforced its balance sheet, raising $9.8 million in capital and receiving a $4.3 million R&D tax incentive refund, extending its cash runway into 2027.

This funding position supports continued clinical progress while allowing the company to explore potential partnering opportunities.

Partnerships and broader pipeline optionality
Beyond PTX-100, the report points to additional upside from Prescient’s pipeline, including its OmniCAR and CellPryme platforms.

These technologies are designed to enhance cell therapy approaches such as CAR-T, addressing limitations around durability, efficacy and control. The company is currently seeking collaborations to advance these programmes, creating additional pathways for value creation.

However, the most significant near-term catalyst remains PTX-100, particularly as Phase 2 data begins to build.

"A pharma partnership — whether in the form of a co-development agreement, regional licensing deal, or broader collaboration — would be a transformative catalyst for Prescient’s valuation and share price."

The report notes that meaningful Phase 2 data will likely be required before major deals are struck, although early engagement with potential partners is already under way.

Valuation highlights upside, with risks in focus
Pitt Street Research has reiterated its valuation range of $0.11 to $0.16 per share, based on a risk-adjusted net present value model incorporating PTX-100, CellPryme and the company’s cash position.

PTX-100 accounts for the majority of that valuation, reflecting its position as the company’s lead and most advanced asset.

At current levels around $0.06 per share, the report implies material upside, contingent on continued clinical progress and successful execution of the Phase 2 programme.

As with all clinical-stage biotech companies, risks remain. Pitt Street notes that for Prescient, these include potential delays in patient enrolment, regulatory uncertainty and the possibility of future capital requirements, alongside the inherent variability of clinical outcomes as trials expand.

According to the researchers, with Prescient’s differentiated mechanism, supportive early data and expanding trial infrastructure, the company is entering a critical period where execution — particularly around enrolment and data delivery — will be key to unlocking that potential.